**Zinc Nutrition and Allied Deficiency Syndrome**

Akefe, I.O., 1 Ayo, J.O, 1 Yusuf, I.L 2

1. Physiology Department, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria

2. Pharmacology and Toxicology Department, University of Maiduguri

akefeisaac@yahoo.com, 08034986335, 08156353662

**Abstract:** Zinc (Zn) is a divalent cation and essential trace element with manifold biochemical and physiological functions. It is abundantly required for the activity of over 300 enzymes, and partakes in many enzymatic, metabolic and neuromodulatory functions in the body. Zn is an indispensable component of DNA-binding proteins and is involved in antioxidant defence and DNA repair. Specific and non-specific neuronal carriers afford Zn entry into central neurones, where the metal ion accumulates in synaptic vesicles. The systemic level of Zn distribution is closely regulated with physiological concentration maintained within the range of 10-20 mM**.** Cellular and subcellular homeostasis is achieved via complex regulation of uptake, distribution, storage, and efflux, in which ZnT and ZIP transporters play primary roles. Zn plays major roles in ion channel modulation, signalling, inhibition of bone loss, anti-inflammation and anti-oxidation. Symptoms associated with Zn deficiency include impairment of prenatal and ante-natal growth and development, neuropsychological performance, diarrhoea, pneumonia, infertility and cancer. Measurement of plasma Zn concentration is essential for diagnosis as less than 50 μg/dl is indicative of severe deficiency of Zn.Enhanced Zn bioavailability and supplementation as single micronutrient or as a component of a multi-micronutrient mix are imperative to prevent Zn deficiency. In conclusion, there is compelling evidence demonstrating detrimental effects associated with Zn deficiency, thus supporting the beneficial role of Zn as a nutripharmaceutical essential for enhancing health and well-being of man and animals.

[Akefe, I.O., Ayo, J.O, Yusuf, I.L. **Zinc Nutrition and Allied Deficiency Syndrome.** *N Y Sci J* 2017;10(6):83-97]. ISSN 1554-0200 (print); ISSN 2375-723X (online). http://www.sciencepub.net/newyork. 12. doi:10.7537/marsnys100617.12.

**Key Words:** Zinc, Antioxidant, Metal, Nutrition, Deficiency, Syndrome

**Introduction**

Zinc (Zn) is the next most abundant and essential trace element in the body after iron. It performs multifunctional biological roles, and up to 10% of all proteins in mammalian cells require Zn for their break-down, conformational modification or activity (Andreini *et al.,* 2006; Prasad, 2013; 2014). Zn is required for the activity of over 300 enzymes, and is therefore involved in many enzymatic and metabolic functions in the body (Andreini *et al.,* 2012). Zn is a divalent cation with manifold biochemical and physiological functions, and it plays principal neuromodulatory roles in the central nervous system. Specific and non-specific neuronal carriers afford Zn entry into central neurones, where the metal ion accumulates in synaptic vesicles. Modulation of excitatory and inhibitory amino acid transmissions is amongst the many putative roles ascribed to brain Zn (Ghasem *et al*., 2016). Indeed, Zn is co-released with glutamate, and it modulates glutamatergic excitation by inhibiting N-methyl-D-aspartate (NMDA) receptors, and averts gamma-aminobutyric acid (GABA) inhibition by blocking GABA-A receptor function (Fregoneze *et al*., 1999). It is also known to be an indispensable component for DNA-binding proteins with Zn fingers, as well as copper/Zn superoxide dismutase and a variety of proteins involved in DNA repair (Ho and Ames, 2002). Thus, Zn plays a vital role in transcription factor function, antioxidant defense and DNA repair.

The aim of this paper, is to review the biochemical and physiological functions, homeostasis, groups at high-risk, nutritional requirement, causes and consequences of zinc deficiency and as well highlight diagnotic and prevention strategies of zinc deficiency. **Sources of Zinc**

A wide variety of foods contain Zn, and good sources usually have 1-2 mg per serving. Oysters contain more than any other food (74 mg/serving), but red meat and poultry provide the majority of Zn in diet. Other food sources with high Zn content include beans, nuts, whole grains, fortified breakfast cereals, and dairy products (Wood, 2000; VNDPG, 2013;

Nunes *et al.,* 2017). Other sources include:

**Legumes**

Tofurky Italian sausage, 1 sausage 9 mg, hummus, ½ cup 2.3 mg, tofu, ½ cup firm, raw 2.0 mg, chickpeas, ½ cup cooked 1.3 mg, lentils, ½ cup cooked 1.3 mg, edamame, ½ cup cooked 1.1 mg, green peas, ½ cup cooked 1 mg, black beans, ½ cup cooked 1 mg, peanut butter, 2 tablespoons 0.9 mg, refried pinto beans, ½ cup cooked 0.9 mg, miso, 1 tablespoon 0.4 mg.

**Vegetables**

Mushrooms, ½ cup cooked 0.7 mg, spinach, ½ cup cooked 0.7 mg, broccoli, ½ cup cooked 0.4 mg, kale, ½ cup cooked 0.2 mg.

**Grains**

Total, ¾ cup 15 mg, wheaties, ¾ cup 7.5 mg, wheat germ cereal, ¼ cup 4.7 mg, rice chex, 1 cup 3.8 mg, oatmeal, 1 cup cooked 2.3 mg, corn, 1 cup 0.9 mg, whole-wheat bread, 1 slice 0.6 mg.

**Nuts and Seeds**

Pumpkin seeds, ¼ cup roasted 2.3 mg, cashews, ¼ cup dry roasted 1.9 mg, sunflower seeds, ¼ cup dry roasted 1.7 mg, almonds, ¼ cup dry roasted 1.1 mg, walnuts, ¼ cup chopped 0.9 mg, nutritional yeast, 1 tablespoon 2 mg.

**Biochemistry of Zinc**

Zn, distinct from iron and copper, is redox neutral and reactive as a Lewis acid in biological reactions. In view of these features, Zn plays crucial roles as a structural, catalytic, and signalling component. As a structural component in proteins, the involvement of Zn with proteins was first acknowledged by the crystallisation of insulin with Zn (Myers *et al.,* 2013). The “Zn finger” motif was first established in the transcription factor TFIIIA of *Xenopus* (Andreini *et al.,* 2011). Zn fingers are now categorised into more than 20 classes of structurally distinct modules and are recognised as a functional motif that interacts with a variety of proteins, lipids, and nucleic acids, clearly indicating the importance of Zn in cellular biochemistry. In catalytic functions, Zn can activate substrates in enzymes by stabilising negative charges, due to its strong Lewis acid property (Maret *et al.,* 2012). After the first identification of Zn in erythrocyte carbonic anhydrase as a Zn-dependent enzyme, the presence of Zn has been documented in many enzymes in all six classes defined in the Enzyme Commission (EC) system (Valle and

Falchuk, 1993; Prasad, 2013, 2014).

Within proteins, Zn can be coordinated by nitrogen, oxygen, and sulphur atoms and can have different coordination numbers (Kochanczyk *et al*., 2015). The Zn proteome estimates that almost 9% of proteins are Zn proteins in eukaryotes with the number significantly greater in higher organisms. The number of Zn proteins encoded by humans is approximately 10%. In Zn proteomes, the number of Zn-binding motifs is counted predominantly based on mining for intramolecular Zn-binding sites (Andreini *et al.,* 2006).

**Zinc Distribution**

The human body mass contains 2-3 g of Zn, and 57% is in skeletal muscle, 29%, 6% and 5% in bone, liver and skin, respectively (King *et al.,* 2000). There is only about 0.1% of total Zn circulating in plasma, and yet this minute fraction of total Zn is essential to maintain Zn homeostasis at a systemic level. Plasma Zn turns over rapidly to meet tissue needs and has to be replenished daily from diet. Once getting into plasma, the dietary Zn is delivered to peripheral tissues. The systemic level of Zn distribution is closely regulated and the physiological concentration of plasma Zn is maintained within the range of 10-20 mM (Meunier *et al.,* 2005; Disilvestrol *et al.,* 2015; Brnic *et al.,* 2016). The plasma Zn concentration is normally around 15 mM in Zn adequate adults and about 11.0-13.5 mM in Zn adequate children. Greater than 70% of plasma Zn is weakly bound to albumin and is mostly derived from intestinal absorption with a destination of the liver and soft tissues (Rukganuer *et al.,* 1997; Disilvestrol *et al.,* 2015).

**Zinc Homeostasis in Cell and in the Body**

After entry of Zn into cells, it is further distributed to diverse cellular organelles; about 30-40 % to the nucleus, 10 % to membranes and at least 50 % to the cytoplasm. The intracellular Zn exists in three pools which include those tightly bound to metalloenzymes, metalloproteins, and nucleoproteins, those loosely bound with diverse protein and amino acid ligands and those unbound as the free Zn2+ ion, albeit at very low concentrations (Rukganuer *et al.,* 1997; Disilvestrol *et al.,* 2015). While the total cellular Zn concentration is estimated to be in mM range, the cytosolic concentration of free Zn2+ is predicted to be in the nM-pM range. The precised determination of free Zn2+ concentration is of importance to the understanding of many Zn-mediated cellular events, yet the reliable measurement of free intracellular Zn2+ and visualisation of its dynamic changes continue to be a technical challenge. This is partly a consequence of the selectivity and sensitivity of Zn probes, which is strongly influenced by the concentrations of Zn and additional cations in living biological systems (Disilvestrol *et al.,* 2015).

The adult human body contains 2–3 g of Zn. Approximately 60 % of Zn is stored in skeletal muscle, 5 % in the liver and skin, 30 % in bone, and the remaining 2–3 % in other tissues (Jackson, 1989). Serum Zn accounts for only 0.1 % of the body's Zn, 80 % of which is loosely bound to albumin and 20 % of that is tightly bound to α2-macroglobulin (Barnett *et al*., 2014), and 0.1 % of the body Zn is replenished daily via diet. The absorption of Zn in the duodenum and jejunum is strictly regulated; it increases up to 90 % when dietary Zn is restricted (Taylor *et al.,* 1991), whereas Zn release, when in excess, is facilitated by the gastro-intestinal secretion, sloughing mucosal cells and integument, and renal excretion (Krebs, 2013).

In general, more than 30 proteins, including ZnT and ZIP transporters, operate under a precisely coordinated regulation for the maintenance of systemic and cellular Zn homeostasis in mammals. No short peptide hormone hepcidin has been identified in Zn to play a vital role as seen in systemic iron homeostasis (Nameth *et al*., 2004; Golan *et al.,* 2015). Study findings reveal that a low-molecular-weight (2 kDa) Zn-regulated humoural factor, which is likely induced in Zn deficiency, controls gene expression predominantly associated with immune functions and development in smooth muscle cells. It is suggested that a different short peptide functions as a humoural factor in systemic Zn homeostasis (Golan *et al.,* 2015).

The cellular and subcellular Zn homeostasis is achieved via sophisticated regulation of uptake, distribution, storage, and efflux, in which ZnT and ZIP transporters play primary roles. Zn mobilisation between intracellular vesicles and organelles by these transporters also contributes to buffer perturbations of cytosolic Zn homeostasis, which is termed “buffering” and “muffling”. Buffering and muffling are essential in situations of excess Zn conditions and also play a role in Zn ion fluctuations (Maret, 2013).

**Zinc Transporters**

**ZIPs and ZnTs**

Maintenance of intracellular Zn homeostasis is mainly dependent on two families of Zn transporters (Fukunaka and Kambe, 2010; Pan *et al*., 2017). In particular, ZIP family proteins function in the uptake of Zn into the cytoplasm of the cell from the extracellular space or from intracellular compartments, such as Golgi apparatus, endoplasmic reticulum (ER), and mitochondria; ZnT proteins function in the efflux of Zn from the cytoplasm to the extracellular space or to intracellular compartments. There are about 14 ZIP transporters and 10 ZnT proteins in the human body with differential tissuespecific expression (Cousins *et al*., 2006; Pan *et al*., 2017). Depending on their degree of sequence conservation, the 14 ZIP proteins can be further organised into 4 subgroups: the ZIP subfamily I, the ZIP subfamily II, the guf-A subfamily, and the LIV-1 subfamily (Gather and Eide, 2006). While the functions of the ZIP subfamily II and the LIV-1 subfamily have been comprehensively investigated, the ZIP subfamily I (ZIP9) and the guf-A subfamily (ZIP11) are less well described. The structural homology and variation among these Zn transporters as well as their tissue distributions and functions have been documented (Cousins *et al*., 2006; Kambe *et al*., 2015).

**Role of Zinc in Ion Channel Modulation**

Zn-regulated channels in the central nervous system has been largely investigated (Marger *et al.,* 2014). Many channels in the CNS excitable cells are regulated by Zn, such as NMDA and GABA receptors, glycine receptors (glyR) and serotonin receptors (5-HT3). The purinergic receptors are adenosine triphosphate (ATP)-gated cation channels at the plasma membrane, with wide cell-type expression, including neurones, cancer and immune cells (Pan *et al.,* 2017). The physiological concentrations of Zn can strongly inhibit human purinergic receptors P2X2 (hP2X2), while Zn enhances current activated by 5 µM ATP in a voltageindependent manner for P2X4 (Punthambaker *et al.,* 2012). Acid-sensing ion channel 3 (ASIC3) is a proton-gated, voltage-insensitive Na(+) channel that plays a key role in pain perception, particularly as a pH sensor following cardiac ischaemia. Zn is reported to be an important regulator of ASIC3 at physiological concentrations, and it inhibits ASIC3 in a pH-and Ca2+-independent manner. The inhibition of ASIC3 currents is dependent upon the interaction of Zn with extracellular domain(s) of ASIC3 (Jiang *et al.,* 2010; Pan *et al.,* 2017).

For large-conductance voltage-and Ca2+activated Slo1 K (BK) channels, intracellular Zn potently and reversibly activates the channel through the regulator of conductance for K+ (RCK1) domain of the channel (Hou *et al*., 2010; Inoue *et al.,* 2015). Zn is also able to modulate a number of subunits of Ca2+ channels, including Cav1.2, Cav1.3, Cav3.1, Cav3.2 and Cav3.3 (Marger *et al*., 2014). In cultured cells exogenously expressing recombinant T-type Ca2+ channels (transient opening Ca2+ channels), that is, Cav3.1, Cav3.2 and Cav3.3, the Cav3.2 current is significantly more sensitive to Zn than that of Cav3.1 and Cav3.3 (Traboulsie *et al*., 2007; Chevallet *et al.,* 2014). Zn can cause a major increase in Cav3.3 current in action potential clamp experiments; while Cav3.1 and Cav3.2 currents are majorly reduced, indicating that Zn exhibits differential modulatory effects on T-type Ca2+ channels. In addition to voltage-gated Ca2+ channels, other Ca2+ channels can be modulated by Zn in general, such as TRP channels. In whole-cell patch-clamp recordings, extracellular application of Zn inhibited TRPM5 currents (Uchida *et al*., 2013). Using mutagenesis approach, it was demonstrated that inhibition by 30 µM ZnCl2 was impaired in TRPM5 mutants in which Histidin at 896, and Glutamine at 926 and/or Glutamine at 939 in the outer pore loop were replaced with Glycine. These data suggest that extracellular Zn inhibits TRPM5 channels through its interaction with the extracellular pore loop domain. Another Zn-modulated unique TRP family member is TRPA1 (Banke and Wickenden, 2009). In this case, the activation of TRPA1 firstly requires Zn influx through the TRPA1 channel which subsequenctly activates the channel itself. Several intracellular cysteine and histidine residues are required for the Zn activation. TRPA1 is highly sensitive to intracellular Zn and nM concetrations are sufficient to activate the channel (Pan *et al.,* 2017).

**Role of Zinc in Inhibition of Bone Loss**

The cellular mechanism of Zn action has been shown to stimulate proliferation and differentiation in osteoblastic cells (Masayoshi and Satoshi, 2003). Zn can stimulate protein synthesis in osteoblastic cells. Zinc has also proven to inhibit the formation of osteoclastic cells from bone marrow cells, indicating that the metal has an inhibitory effect on bone resorption. Consequently, Zn may play a role in the preservation of bone mass by stimulating bone formation and inhibiting bone resorption. A Zn compound, ß-alanyl-L-histidinato Zn, has preventive and therapeutic effects on different experimental osteopenia with ageing, skeletal unloading, aluminium toxicity, hydrocortisone treatment, low-calcium and vitamin D-deficient diets, inflammation, and ovariectomy treatment *in vivo.* The anabolic effect of ßalanyl-L-histidinato Zn on bone components has been shown to be more than that of Zn sulphate (Masayoshi and Satoshi, 2003). It has been reported that Zn acexamate has a potent effect on bone formation as compared with that of ß-alanyl-Lhistidinato Zn *in vitro* (Masayoshi and Satoshi, 2003; Biaggio *et al*., 2014). Zn compound may be a good tool in therapy of osteoporosis. Results demonstrate that the administration of Zn acexamate has a preventive effect on bone loss in streptozotocindiabetic rats *in vivo.*

**Zinc Action as Anti-Inflammatory Agent**

Necrotic factor-κB (NF-kB) is one of the major immune response transcription factors involved in molecular signalling. Zn plays an essential role in activation of NF-κB. The regulation of NF-κB activation by Zn is, however, cell specific (Prasad *et al*., 2004; Prasad, 2014). It has been reported that Zn is required for NF-κB DNA binding in purified or recombinant NF-κB p50 protein in T helper cell lines (Prasad *et al.,* 2001). Prasad *et al.* (2001) stated that normal healthy volunteers who were supplemented with 45 mg elemental Zn daily had a significant reduction in TNF-α and IL-1β messenger RNAs and TNF-α-induced NF-κB DNA binding in isolated peripheral blood mononuclear cells in comparison to placebo-treated subjects (Prasad *et al.,* 2004). Zn has been reported to upregulate the expression of A20 in HL-60 cells. It decreases ox-LDL-induced generation of TNF-α, IL-1β, and VCAM-1, oxidative stress markers in the plasma and activation of NF-κB, and increases A20 and PPAR-α protein in human monocytic and vascular endothelial cells (Bao *et al*., 2010; Prasad, 2014). Zn is believed to inhibite NF-κB activation via A20, a Zn finger transactivating factor that plays an essential role in down regulating IL-1β and TNF-α-induced NF-κB activation. A20 was originally thought to protect cells from TNF-αinduced cytotoxicity by inhibiting the activation of NF-κB, resulting in lower IL-1β and TNF-α signalling in endothelial cells (Bao *et al*., 2010). It was shown that A20 inhibits NF-κB signalling by TNF-α and IL1β via TNF-receptor-associated factor pathways in endothelial cells (Bao *et al*., 2010; Prasad, 2014).

The PPAR-α and -γ of nuclear receptors, the mediators of lipoprotein metabolism, inflammation, and glucose homeostasis were shown to play a protective role in the development and progression of atherosclerosis. The mechanism by which Zn may exert athero-protective role is most likely due to its anti-inflammatory effect. Zn-sufficient HAEC cells have been shown to increase PPAR-α concentration compared with Zn-deficient HAEC cells, which suggested that Zn increases the expression of PPAR-α protein, apparently contributing to down-regulation of inflammatory cytokines and adhesion molecules. It is proposed that the down-regulation of NF-κB activation by Zn via A20-PPAR-α signalling pathways results in decreased generation of inflammatory cytokines, which protects the endothelial cells from atherosclerosis (Prasad, 2014).

**Antioxidant Role of Zinc**

Ghasem *et al*. (2016), reported that Zn supplementation greatly augmented the fertilisation capacity of male rats exposed to noise stress. The ameliorative effect of Zn has been attributed to its antioxidant potential to scavenge reactive oxygen species produced following exposure to noise and other stress factors (Ghasem *et al.,* 2016).

The effect of Zn on hepatic lipid peroxidation and antioxidative enzymes in ethanol-fed rats has also been demonstrated. Alcoholic liver disease may be caused by reactive oxygen species (ROS) generated during the metabolism of ethanol by a microsomal ethanol-oxidising system. Increased formation of ROS and enhanced hepatic lipid peroxidation have been reported after acute and chronic ethanol consumption, and are linked with the development of hepatic injury (Khalaf *et al.,* 2017). Feeding of ethanol to rats has been confirmed to augment the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) and diminish the activity of catalase in rat liver. Zn supplementation to ethanol-intoxicated rats notably stabilises the increased activities of oxidative stress-related enzymes (viz. catalase, SOD and GPx) as well as decreases lipid peroxidation; thus, signifying its antiperoxidative potential. This antioxidative role of Zn appears to be the fundamental process whereby it restores the structural as well as functional integrity of the liver under ethanol toxicity. In addition, to a large extent Zn regulates the activities of enzymes of the antioxidative system as well as reduces lipid peroxidation (Nunnes *et al.,* 2017).

Zn deficiency aggravates the increase in ROS formation in ovariectomised rats, but its supplementation prevents the formation of ROS (Baltaci *et al*., 2004). It has also been proposed that the augmentation of lipid peroxidation by cadium in rats is a result of a decrease in SOD and CAT activities. Zn supplementation prior to cadium administration averts several of the effects, observed when cadium is administered alone (Jemaia *et al.,* 2007). Result indicates that one of the mechanisms involved in the protective role of Zn against cadiuminduced toxicity is connected with inhibition of cadium-induced ROS formation. The role of Zn in protecting biological structures from ROS damage is due to several factors: first, by maintaining an adequate level of metallothionein, which is also a scavenger of ROS; then, as an essential structural component of Cu/Zn SOD; and finally, as a protective agent for thiols and additional chemical groups (Jemaia *et al.,* 2007). It has been shown that cadium induces a decline in erythrocyte counts, SOD and CAT activities, and an increase in lipid peroxide concentration in plasma. Zn supply on exposure to cadium shields against the cadium-induces decrease in SOD activity and might partially protect against Cdinduced lipid peroxidation (Jemaia *et al.,* 2007). Zn is also an incredibly essential supplement during administration of chelating agents in lead treatment, especially when using Ethelenediaminetetraacetic acid and dimacaprol as it has also been accounted to scavenge ROS released in the process (Grogorescu *et al.,* 2015).

**Mechanism of Zinc Action as an Antioxidant**

Zn operates as an antioxidant by different mechanisms. Principally, it competes with iron (Fe) and copper (Cu) ions for binding to cell membranes and proteins, displacing these redox active metals, which catalyses the formation of OH from H2O2 (Bao *et al.,* 2013). Zn also binds to (SH) sulfhydryl groups of bio-molecules, shielding them from oxidation. It increases the activation of antioxidant proteins, molecules, and enzymes such as glutathione (GSH), catalase, and SOD and also attenuates the activities of oxidant-promoting enzymes, such as inducible nitric acid synthase (iNOS) and NADPH oxidase, and inhibits the generation of lipid peroxidation products. Zinc also instigates the expression of a metal-binding protein metallothionein (MT), which is very rich in cysteine and is an excellent scavanger of OH ions (Bao *et al.,* 2013; Gao *et al.,* 2014). Nuclear factor erythroid 2-related factor 2 (Nrf2), a family member of cap’n’ collas/basic leucine zipper (CNC-bZIP) proteins is a vital transcription factor that regulates the gene expression of antioxidant proteins and enzymes such as GSH and SOD, as well as detoxifying enzymes such as glutathione-*S*-transferase-1 (GSTA1) and haemeoxygenase-1 (HO-1), by binding to an antioxidant responsive element (ARE) in the promoter region of the target gene. Several studies have demonsrated that Zn may have a regulatory role in Nrf2, since it up-regulates Nrf2 activity and attenuates oxidative stress (Bao *et al.,* 2013).

**Zinc Signalling**

The signalling functions of Zn is very crucial and occurs by increase in Zn (Zn2+) concentrations, triggered by stimuli. Zn-activated signalling is associated with pathophysiological functions (Fakada and Kambe, 2011) and thus, has therapeutic potential. Extracellular release of Zn acts as a signalling mediator in endocrine, paracrine, and autocrine systems. In the CNS, Zn, which is released from presynaptic neurones following excitation into synaptic clefts, modulates synaptic transmission by binding to various transporters and receptor channels on postsynaptic neurones (Takada *et al*., 2013). Zn, co-released from pancreatic β-cells along with insulin by glucose stimuli, can suppress hepatic insulin clearance and diminish insulin secretion from the βcells (Tamaki *et al.,* 2013). Extracellular release of Zn binds to diverse cell surface proteins, and the most intriguing protein is the Zn receptor, the G proteincoupled receptor 39 (GPR39) (Sharir *et al.,* 2010).

Zn plays vital signalling roles as a second messenger in the cytosol (Fakada and Kambe, 2011); where Zn signalling is instigated by Zn influx, which originates from extracellular sites and from intracellular organelles. “Zn wave” refers to Zn released from the perinuclear area, including the endoplasmic reticulum (ER) which has been shown to be important for cell signalling functions (Taylor *et al*., 2012). Moreover, Zn, released from cytosolic proteins with oxidation-sensitive Zn-binding sites such as metallothionein (MT) via oxidative stimuli, is also involved in intracellular Zn signalling (Aras *et al.,* 2011; Nunnes *et al*., 2017). Intracellular Zn signalling is divided into several categories according to the time-scale in which it acts (Haase *et al.,* 2014). “Fast” or “early” Zn signalling occurs within seconds to minutes after stimulation and does not require transcription of proteins (Haase *et al.,* 2008). Conversely, “late” Zn signalling requires biosynthesis of proteins to control cytosolic Zn concentrations and occurs over a period of hours after stimulation (Kitamura *et al.,* 2006). The word “late” Zn signalling is commonly used to contrast with the word “fast” or “early” Zn signalling. This term portrays the downstream effects mediated through changes in gene expression, not signalling events. Prominently, intracellular Zn signalling targets a number of enzymes, involved in cellular signalling, including protein tyrosine phosphatases (PTPs) (Wilson *et al.,* 2012) phosphodiesterases (PDEs) (Hajyo *et al*., 2011), calcineurin (Aydemir *et al*., 2009), caspases (Miyai *et al.,* 2014) and diverse kinases such as mitogenactivated protein kinase (MAPK) and protein kinase C (PKC) (Hasson *et al.,* 1996). Physiological levels of intracellular free Zn2+ concentrations regulate activities of these enzymes. For example, inhibition of caspase-3, T-cell PTP, and PTP-1B is achieved with IC50 values below 10, 200, and 17 nM, respectively (Haase and Maret, 2003). Inhibition of the activity of PTPs by Zn is commonly operative in intracellular Zn signalling. The enzymatic activity of caspase-9 is reversibly inhibited by Zn binding to cysteine and histidine residues in the active site, and similar reversible inhibition mechanisms operate in other enzymes such as PTPs (Haase and Maret, 2005). Specifically, inhibition of PTP-1B activity by Zn is possibly mediated via a cysteinyl-phosphate intermediate (Bellomo *et al.,* 2014).

**Zinc Level Detection**

Lack of ample laboratory biomarkers (Wood, 2000; Wu *et al.,* 2015) and the inadequacy of pathognomonic clinical features of Zn deficiency states are key factors, hampering the detection of Zn deficiency states. Measurements of Zn concentrations in plasma are useful in identifying children, who are more likely to have a growth response to Zn supplements (Brown 1998) or diarrhoea (Bahl *et al.* 1998). The potentially confounding factor of hypozincaemia as part of the acute phase response to infection may not be a foremost detriment. Unfortunately, however, this assay lacks the sensitivity required to give it a strong endorsement as a biomarker of Zn status. The application of other indices, such as hair Zn concentrations, although capable of yielding interesting and useful data (Ferguson *et al.* 1993), has been even less well defined. An example is the activity of a Zn-dependent enzyme. Consequently, elucidation of the prevalence and the clinical effects of milder Zn deficiency states has depended, to a very large extent, on the results of well-designed and executed, controlled, randomised intervention trials with dietary Zn supplements. Such trials have made fundamental contribution to recent progress (Bostanci *et al.,* 2015).

**Physiological Changes Associated With Zinc**

**Inbalance**

**Hyperzincaemia**

Excess Zn is proven to be toxic to cells, especially to neurones. Acute toxicity from Zn poisoning affects the respiratory and gastro-intestinal systems and is typified by nausea, vomiting, loss of appetite, abdominal cramps and headaches. Excess Zn in neuronal and glial cells is associated with a variety of excitotoxicity conditions, such as epilepsy, ischaemia, brain trauma, and neuro-degenerations in Alzheimer’s disease. Conversely, the evidence for significant toxic effects of Zn in humans is limited to accidental exposure to compounds of high Zn concentration and these cases are rather rare (Bostanci *et al.,* 2015).

**Clinical Manifestations of Zinc Deficiency**

The symptoms may be very severe and even fatal if not recognised and treated promptly by Zn, such as seen in patients with acrodermatitis enteropathica (AE). AE is a genetic disorder mainly affecting infants of Italian, Armenian, or Iranian lineage (Bao *et al.,* 2010). The manifestations include bullous pustular dermatitis, particularly around the orifices. Opthalmic signs include blepharitis, conjunctivitis, photophobia, and corneal opacities (Prasad, 2013, 2014).

Neuropsychiatric signs include irritability, emotional instability, tremors and cerebellar ataxia, weight loss, growth failure, and male hypodonadism are prominent features. Congenital malformation of foetuses and infants born of pregnant women with AE has been reported frequently (Cavdar *et al.,* 1980; Prasad, 2014).

Acrodermatitis enteropathica patients are very susceptible to infections. Thymic hypolasia and plasmacytosis in the spleen are commonly seen in experiment animals. T cell-mediated immune disorders are corrected by Zn supplementation. Without Zn supplementation, the clinical course is downhill with failure to thrive and complicated by intercurrent bacterial, viral, fungal, and opportunistic infections. Gastro-intestinal manifestations include diarrhoea, malabsorption, steatorrhoea, and lactose intolerance. Zn supplementation in therapeutic doses (in excess of 50 mg elemental Zn daily) results in complete recovery (Prasad, 2013; 2014).

**Allied Zinc Deficiency Syndrome**

The deficiency of Zn predisposes the patient to several pathological alterations resulting in severe health impairments in several aspects, some of which have been reviewed below:

**Effect of Zinc Deficiency on Pregnancy and Prenatal Development and Child Health**

Recent studies are now focused on pregnancy and the effects of maternal Zn status on both prenatal and postnatal development (Caulfield 1999a). Early results of these endeavors indicate that poor maternal Zn status in pregnancy can have detrimental effects on foetal brain function (Merialdi *et al.* 1998). In contrast to recent observations in the United States (Goldenberg *et al.* 1995), the lack of effect of maternal supplementation on foetal growth has been unexplained (Caulfield *et al.,* 1999b).

It has been estimated (Zn for Child Health, 1997) that the beneficial effects of Zn supplements for diarrhoea prevention are of the same magnitude as those achieved by cleaning the water supply and providing quality sanitation. In the case of children under 5 years, the public health benefits of Zn supplementation in the prevention of acute lower respiratory disease and malaria have also been calculated to be superior to any other preventive modalities (Black, 1998). These nutritional diseases are the principal causes of childhood morbidity and mortality globally. The impairment of physical growth and that of neuropsychological development are wellrecognised related features. The sum of recent evidence indicates that the maintenance of optimal Zn nutrition is perhaps the most effective, even if only partial, preventive measure that can be undertaken to reduce morbidity rates in young children in the developing world (Alam *et al.,* 2017).

**Zinc Deficiency and Impaired Growth**

The one clinical feature that is most studied is the impairment of physical growth. As with other features of Zn deficiency, the most definitive investigations have been those based on randomised, controlled studies of dietary Zn supplementation. In the Colorado studies in the 1970s and 1980s, the principal focus was on physical growth. The principal reason for this focus was the earlier, clear demonstration in animal models that Zn had little pharmacological effect on growth (Bostanci *et al.,* 2015). Consequently, the demonstration of an increase in growth velocity associated with modest dietary Zn supplements under double-blind, controlled, randomised study conditions provided convincing evidence for a pre-existing growth-limiting Zn deficiency state. In all, four of such studies were undertaken in Colorado. Subjects ranged from healthy cow’s milk formula–fed infants (Walravens and Hambidge, 1976), at a time before Zn fortification of cow’s milk formulas became the norm, to older infants, toddlers or young children with non-organic failure to thrive. Consequently, many other studies of

Zn supplementation have included growth measurements. These results have been subjected to rigorous and repeated meta-analysis with confirmation of the effect of Zn supplements in increasing height and weight velocity, when administered to children in many countries (Brown *et al.* 1998).

In some cases, effects have been observed on body composition rather than on weight or on linear growth velocity (Kikafunda *et al*. 1998). These different responses serve as a reminder of how much there remains to be learned about variations in the presentation of Zn deficiency and theie responsible factors. They are also a reminder that the biochemical and hormonal factors underlying these effects on growth remain unclear. One of the environmental issues of note is the total diet, including concurrent deficiencies or imbalances of other micronutrients (Solomons *et al*. 1999).

**Zinc Deficiency and Diarrhoea.**

One of the recent strategies made to minimise the diarrhea-associated mortality in children involves the use of oral Zn in diarrhoea management (Alam *et al*., 2017). The inadequacy of dietary Zn uptake is aggravated by the net loss of Zn during diarrhoea. Zn is enlisted in WHO essential drug list under medicine for diarrhea, where it is indicated in acute diarrhoea as an adjunct to oral rehydration salts (Alam *et al*., 2017).

That Zn added to conventional therapy is effective in reducing the duration of acute and persistent diarrhoea has been confirmed via pooled analysis of data derived from multiple studies (Bhutta *et al.* 1999). The severity of the illness may also be reduced. Pooled analyses have also confirmed that Zn supplementation of children at a community level in the developing world results in significant decrease in the incidence and prevalence of diarrhoea. Losses of Zn via the intestine are likely to be increased in diarrhoeal states and may contribute to Zn deficiency and to a vicious cycle. Supplementation trials have not always included rigorous or perhaps any data on habitual diet, although it seems very likely that dietary intake of bioavailable Zn is typically low in the populations studied. More attention to these factors in future studies will be helpful in determining aetiology as well as paramount prevention strategies (Alam *et al*., 2017).

Long-term recognition exists that diarrhoea is characteristically, albeit not inevitably, a prominent feature of acrodermatitis enteropathica, which is a severe form of Zn deficiency. The plausible mechanistic explanations for the links between Zn deficiency and diarrhoea, example is the functional impairment of the immune system and of intestinal mucosal cell transport mechanisms (Ghishan 1984). The modest supplements requisite to achieve a beneficial effect; and, perhaps above all, the concurrent increase in growth velocity are all compatible with the conclusion that the favourable effects on diarrhoea are attributable to correction of a Zn deficiency state that is the cause of, or contributing to the diarrhoea (Bostanci *et al.,* 2015).

**Zinc Deficiency and Pneumonia**

Pooled analyses of the results of community Zn supplementation studies in children in developing countries have demonstrated a very substantial and statistically significant reduction in the prevalence of pneumonia (Bhutta *et al.* 1999).

Infections such asmalaria appear to be reduced by Zn supplementation (Black, 1998). **Effect of Zinc Deficiency on Neuropsychological performance**

Evidence of improved brain development attributable to improved Zn status has originated from studies of activity levels in young children in India (Sazawal *et al.* 1996) and Guatemala (Bentley *et al.* 1997). Neuropsychological performance has been reported to improve with Zn supplementation in young Chinese children (Sandstead *et al.* 1998), but only when other micronutrient nutrition is sufficient. Zn has been confirmed to enhance learning and memory due to its antioxidant potential to scavenge ROS and protect neuronal degeneration in animals subjected to acute stress conditions (Prasad, 2013, 2014).

**Zinc Deficiency and Infertility**

Zn losses have been reported to occur through menstruation in women and ejaculation in males; especially as semen has a high Zn concentration. In males, Zn concentration in seminal plasma is known to correlate with sperm count, motility and viability, although studies report conflicting findings about the magnitude of these correlations and whether concentrations are higher or lower in subfertile compared to fertile men; probably explained by between-study differences in inclusion criteria (Agarwal *et al*., 2010). Although the underlying mechanisms by which Zn affects spermatogenesis remain unknown, the positive effects of Zn on sperm count and parameters (morphology and motility) are documented (Ghasem *et al.,* 2016). The ability of Zn to reduce oxidative stress in sperm has also been identified, although this was negatively associated with sperm decondensation (Agarwal *et al*., 2010). Even when Zn supplementation far surpasses the recommended daily intake, a concurrent increase in circulating or local concentrations of Zn or FSH and testosterone are not always evident; possibly explained by the absence of Zn deficiency or high excretion by the prostate. In females, serum Zn concentrations are almost twice as high as follicular concentrations, although the high expression of Zn transport genes in the oocyte suggests active Zn transport during the first stages of pre-implantation development (Ozkaya *et al.,* 2011; Golan *et al*., 2015). Similar to studies in males, studies have reported conflicting results as to whether differences exist in serum Zn concentrations between infertile and fertile women (Menezo *et al.,* 2011). Lower follicular fluid and serum Zn and selenium levels were found in IVF patients than in fertile women (Menezo *et al.,* 2011), with normalisation to those of fertile women following multivitamin supplementation (Ozkaya *et al.,* 2011), although the effect on pregnancy rate was not studied. Zn consumption is also very beneficial in reducing the detrimental effects of noise pollution in rats (Ghasem *et al.,* 2016).

**Zinc Deficiency and Cancer**

Although serum or plasma Zn is not a good biomarker for Zn deficiency, there is compelling evidence that dysregulated Zn homeostasis is indeed associated with many cancers (Pan *et al.,* 2017). Manifold studies show that serum Zn levels are usually low in patients with certain cancers, including malignant prostate cancer (Christudoss *et al.,* 2011), oesophageal squamous cell carcinoma (Abnet *et al.,* 2005; Alam *et al.,* 2017), breast cancer (Vimala *et al*.,

2017) and ovarian cancer (Alam and Kelleher *et al.,* 2012). Normal physiological concentrations of Zn inhibit cancer cell proliferation and migration, maintain balanced metabolism and promote apoptosis in cancer cells (Vimala *et al*., 2017). In consequence, Zn deficiency appears to be involved in every aspect of cancer cell generation and growth. The anti-cancer function of Zn has been widely studied in prostate cancer. The normal human prostate stores the highest content of Zn of all soft tissues in the body, with a typical Zn content more than 1000 µg/g dry tissue (Nunnes *et al*., 2017). The accumulation of Zn by prostate glandular epithelial cells is essential for the specialised function of these cells: to produce and secrete enormously high levels of citrate. During the transformation from prostatic epithelial hyperplasia to carcinoma, a reduction in Zn concentration occurs at a relative early stage and continues throughout tumour progression towards the androgen-resistant stage in prostate cancer patients. Zn contents in the prostate at the malignant stage can decline to as low as 150 µg/g dry tissue, which in turn significantly decreases the production of citrate in the prostate. Concurrently, the plasma Zn levels in patients with prostate carcinoma are much lower than those in healthy subjects or in patients with benign prostatic hyperplasia (Nidia *et al.,* 2016). A number of recent studies suggest that Zn deficiency is more than a by-stander or “passenger” during the carcinogenesis and tumourigenesis. For example, the Akt-Mdm2-p53 signalling axis in human normal prostate epithelial cells (PrEC) was activated as response to Zn deficiency, while the Akt-p21 signalling axis was stimulated in malignant prostate LNCaP cells under the same condition (Han *et al*., 2009; Pan *et al*., 2017). As a result, LNCaP cells but not PrEC cells survived better and progressed through the G0/G1 phase of the cell cycle at Zn deficient conditions (Han *et al*., 2009; Pan *et al*., 2017). Golovine *et al*. (2008) showed that physiological levels of Zn suppressed NF- kB activity and reduced expression of pro-angiogenic and pro-metastatic cytokines VEGF, IL-6, IL-8, and MMP-9 associated with negative prognostic features in prostate cancer (Golvine *et al*., 2008). Selective Zn deficiency initiated by the Zn chelator N, N, N’, N’-tetrakis (2pyridylmethyl)-ethylenediamine (TPEN) increased activation of NF- kB and up-regulates expression of the NF- kB controlled pro-angiogenic and prometastatic cytokines VEGF, IL-6 and IL-8. Reports support the contention that Zn deficiency may contribute to tumour progression via increased expression of the NF-kB-dependent pro-tumourigenic cytokines (Golvine *et al*., 2008; Brnic *et al.,* 2016).

Kambe *et al*. (2015) have conducted serial studies using N-nitrosomethylbenzylamine (NMBA) induced esophageal cancer rat or mouse models to understand the impact of dietary Zn deficiency on carcinogenesis and tumour development. In these studies, the animals were fed with either Zn-deficient or Zn-sufficient diet. The data confirmed that the tumour incidence increased from 6% in the Znsufficient group to 100% in the Zn-deficient group at 11 weeks after NMBA treatment (Wu *et al.,* 2015). Using *in vivo* bromodeoxyuridine (BrDU) labeling followed by immunohistochemical detection of cells in S-phase, they further showed that Zn deficiency notably increased cell proliferation in oesophageal epithelial cells, with shortened lag time for tumour induction. In cultured esophageal cancer cells, reports from a number of groups suggest that replenishment of Zn inhibits proliferation and induces apoptosis. In the same vein, the replenishment of Zn in the diet could reduce cell proliferation and induce apoptosis in esophageal epithelia and, thus, greatly reduce both incidence and size of tumour in the oesophagi and fore-stomach of treated animals (Bae *et al.,* 2016).

Studies revealed no difference in serum Zn levels between breast cancer patients and controls (SMD (95%CI):-0.65[-1.42, 0.13]). However, the hair Zn levels were lower in women with breast cancer, compared with those of control subjects (SMD (95%CI):-1.99[-3.46,-0.52]). Using a Zn-deficient mouse model, Bostanci *et al*. (2015), demonstrated that marginal Zn intake creates a toxic microenvironment in the mammary gland impairing breast development, which could increase the risk for breast disease and cancer (Bostanci *et al.,* 2015).

It is meaningful to note that breast biopsies from breast cancer patients contain significantly higher Zn levels, compared with normal breast tissue. Epidemiological studies have established a relationship between high breast tissue Zn levels and development of breast cancer (Cui *et al.,* 2007; Pan *et al.,* 2017). It seems paradoxical since breast cancer patients have low Zn levels in hair or serum, and Zn deficiency is thought to contribute to the development of breast cancer. These studies suggest that the dysregulated Zn homeostasis is complicated, and relates not only to Zn concentrations, but also to its distribution as well as its temporal pattern (Chandler *et al.,* 2016). The high Zn content in breast tumour tissues implies that cancer cells selectively increase Zn uptake or reduce Zn efflux via regulating one or more Zn transporters (Pan *et al.,* 2017). **Diagnosis of Zinc Deficiency**

Recommended daily dietary allowances (RDA) for infants up to 1 year is 3–5 mg, for children from 1 to 10 years is 10 mg, and for adults (both males and females) it is 15 mg. For pregnant women, RDA is 20 mg and for lactating women RDA is 25 mg (Prasad, 2013, 2014). Currently, the most widely used test for diagnosing Zn deficiency in humans is the determination of plasma Zn level. Normal levels of plasma Zn in adults and children are 100 ± 10 μg/dl. Values below 80 μg/dl will be considered to be in the deficient range. Measurement of plasma Zn by flameless atomic absorption specifically is useful, provided the sample is not haemolysed or contaminated. In patients with acute stress or infection, Zn from the plasma pool may redistribute to other compartments, thus making the diagnosis of Zn deficiency difficult. Intravascular haemolysis would also increase the plasma Zn level, in as much as the Zn in the erythrocytes is much higher than in the plasma (Bao *et al*., 2010). Plasma Zn level of <50 μg/dl would be indicative of severe deficiency of Zn (Prasad, 2013; 2014; Chavellet *et al.,* 2014).

Determination of Zn in the lymphocytes, plasma somatomedin activity, and measurement of IL-2 mRNA in PHA stimulated mononuclear cells by reverse transcriptase (RT)-polymerase chain reaction (PCR) are the most sensitive tests for diagnosing Zn deficiency in humans (Prasad *et al.,* 1993).

**Prevention and Management of Zinc Deficiency**

Research studies have emphasised the ubiquity of Zn in biology and the dependence of a wide range of vital metabolic processes on an adequate supply of this metal. As observed in all nutrients, the challenge is to achieve intakes of bioavailable Zn and tissue levels within a physiological range. It has become more apparent that there is a cost to pay for intakes and levels above this range. Presently, this is commonly considered to be a total of 50 mg elemental Zn per day for adults, with levels of intake for children that are less clear. It is imperative to be appropriately sensitive to this upper limit, even if a decision is made to temporarily exceed this for anticipated (but often uncertain) pharmacological benefits. It is even more essential to be aware that these upper limits are for total daily intake, which may be higher than anticipated due to the increasing trend to fortify foods with Zn. Recently, major intervention approaches for tackling zinc deficiency comprises of dietary supplementation, fortification, modification/diversification, and bio-fortification. The use of Zn, as a single micronutrient supplement, for research purposes has proved priceless, and such studies will continue to have an important role in advancing our understanding of the prevalence and effects of human Zn deficiency. There is already, however, also an important role for studies that include arms for multi-nutrient supplements and, even more important, for studies of dietary modifications that affect mineral bioavailability, whether these are at a local community level or involve more global strategies. Meanwhile, widespread Zn supplementation either as a single micronutrient or as a component of a multi-micronutrient mix is a good preventive measure (Prasad, 2013; 2014).

**Concluding Remarks**

|  |  |  |
| --- | --- | --- |
|  **Schematic Representation of Zinc Nutrition and Deficiency Syndrome.**

|  |  |
| --- | --- |
| **References** 1. Abnet, C. C., Lai, B., Qiao, Y. L., Vogt, S., Luo, X. M., Taylor, P. R., Dong, Z. W., Mark S. D., and Dawsey. S. M. (2005). Zinc concentration in  | esophageal biopsy specimens measured by x- ray fluorescence and oesophageal cancer risk. *Journal of National Cancer Institute*, 97(4): 301306.  |

 |

Zn is an essential trace element that plays major biochemical and physiological roles in the body. It is essential for ion channel modulation, signalling, inhibition of bone loss, anti-inflammation, antioxidation and alleviation of symptoms associated with Zn deficiency, manifested by impairment of prenatal and antenatal growth and development, neuropsychological performance, diarrhoea, pneumonia, infertility and cancer. Enhanced Zn bioavailability and supplementation as single micronutrient or as a component of a multimicronutrient mix is imperative to preventive Zn deficiency. Zn is a nutri-pharmaceutical essential for enhancing health and wellbeing of man and animals.

1. Agarwal, A. and Sekhon, L. H. (2010). The role of antioxidant therapy in the treatment of male infertility. *Human Fertility,* 13: 217-225.
2. Alam, K., Poudel, A., Palaian, S. and Koirala, B. (2017). Role of Zinc in childhood diarrhoea management: a case of Nepal. *Journal of Pharmacy Practice and Community Medicine*, 3 (1): 34-36.
3. Alam, S. and Kelleher, S. L. (2012). Cellular mechanisms of Zinc dysregulation: a perspective on Zinc homeostasis as an aetiological factor in the development and progression of breast cancer. *Nutrients*, 4(8): 875-903.
4. Andreini, C., and Bertini, I. (2012). A bioinformatics view of Zinc enzymes. *Journal of Inorganic Biochemistry*, 111: 150-156.
5. Andreini, C., Banci, L., Bertini, I. and Rosato, A. (2006). Counting the Zinc-proteins encoded in the human genome. *Journal of Proteome*

*Research*, 5 (1): 196-201.

1. Andreini, C., Bertini, I. and Cavallaro, G*.* (2011).Minimal functional sites allow a classification of Zinc sites in proteins. *PLoS One,* 6: 26325.
2. Aras, M. A. and Aizenman, E. (2011).Redox regulation of intracellular Zinc: molecular signalling in the life and death of neurones. *Antioxidant and Redox Signal,* 15: 2249 -2263.
3. Aydemir, T. B., Liuzzi, J. P., McClellan, S. and

Cousins, R. J. (2009)*.* Zinc transporter ZIP8 (SLC39A8) and Zinc influence IFN-gamma expression in activated human T cells. *Journal of Leucocyte Biology,* 86: 337–348.

1. Bae, S. N., Lee, K. H, Kim, J. H., Lee, S. J. and Park, L. O. (2016). Zinc induces apoptosis on cervical carcinoma cells by p53-dependent and independent pathway.*Biochemistry and Biophysics Research Communication,* 291(16): 32137-32144.
2. Bahl, R., Bhandari, N., Hambidge, K. M. and Bhan, M. K. (1998). Plasma Zinc as a predictor of diarrhoeal and respiratory morbidity in children in an urban slum setting. *American Journal of Clinical Nutrition,* 68: 414-417.
3. Baltaci, A. K., Sunar, F., Mogulkoc, R. and Oztekin, E. (2004). The effects of Zinc deficiency and supplementation on lipid peroxidation in bone tissue of ovariectomised rats. Toxicology, 203: 77–82.
4. Banke, T. G. and A. D. Wickenden, A. D. (2009). Intracellular Zinc irritates TRPA1. *National journal of Biological Chemistry*, 5(3): 141-142.
5. Bao, B., Ahmad, A., Azmi, A., Li, Y., Prasad, A. S. and Sarkar, F. H. (2013). The biological significance of Zinc in inflammation and aging.

In: Rahman, I., Bagchi, D., editors. *Inflammation, Advancing and Nutrition*. New York, NY: Elsevier Incorporated. 15–27.

1. Bao, B., Prasad, A. S., Beck, F. W. J., Fitzgerald, J.T., Snell, D., Bao, G. W. (2010). Zinc decreases C-Reactive protein, lipid peroxidation, and implication of Zinc as an atheroprotective agent. *American Journal of Clinical Nutrition,* 91: 1634–1641.
2. Barnett, J. P., Blindauer, C. A., Kassaar, O.,

Khazaipoul, S., Martin, E. M., Sadler, P. J.,

Stewart, A. J. (2013)*.* Allosteric modulation of

Zinc speciation by fatty acids*. Biochim Biophys Acta,* 1830: 5456–5464.

1. Bellomo, E., Massarotti, A., Hogstrand, C., Maret, W*.* (2014).Zinc ions modulate protein tyrosine phosphatase 1B activity*. Metallomics,* 6: 1229–1239.
2. Bentley, M. E., Caulfield, L. E., Ram, M.,

Santizo, M. C., Hurtado, E., Rivera, J. A., Ruel,

* 1. T. and Brown, K. H. (1997). Zinc supplementation affects the activity patterns of rural Guatemalan infants. *Journal of Nutrition,* 127: 1333-1338.
1. Bhutta, Z. A., Black, R. E, Brown, K. H.,

Gardner, J. M., Gore, S., Hidayat, A., Khatun, F., Mortorell, R., Ninh, N. X., Penny, M. E., Rosado, J. L., Roy, S. K., Ruel, M., Sazawal, S. and Shankar, A. (1999). Prevention of diarrhoea and pneumonia by Zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. *Journal of Paediatrics*, 135: 689-697.

1. Biaggio, V. S., Alvarez-Olmedo, D. G., Perez

Chaca, M. V., Salvetti, N. R., Valdez, S. R.,

Fanelli, M. A, Ortega, H. H., Gomez, N. N., Gimenez, M. S. (2014). Cytoprotective mechanisms in rats lung parenchyma with Zinc deprivation. *Biometals,* 27(2): 305–315.

1. Black, R. E. (1998). Therapeutic and preventive effects of Zinc on serious childhood infectious diseases in developing countries. *American Journal of Clinical Nutrition*, 68: 476-479.
2. Bostanci, Z., Mack, Jr R. P., Lee, S., Soybel, D. I., Kelleher, S. L. (2015). Paradoxical Zinc toxicity and oxidative stress in the mammary gland during marginal dietary Zinc deficiency. *Reproductive Toxicology,* 54: 84–92.
3. Brnic, M., Wegmuller, R., Melse-Boonstra, A., Stomph, T., Zeder, C., Tay, F. M. and Hurrell, R. F. (2016). Zinc Absorption by Adults Is Similar from Intrinsically Labeled Zinc Biofortified Rice and from Rice Fortified with Labeled Zinc Sulfate. *Journal of Nutrition*, 146(1): 76-80.
4. Brown, K. H. (1998). Effect of infections on plasma Zinc concentration and implications for

Zinc status assessment in low-income counties. *American Journal of Clinical Nutrition*. 68: 425429.

1. Caulfield, L. E., Zavaleta, N. and Figueroa, A. (1999a). Maternal Zinc supplementation does not affect size at birth or duration of pregnancy in Peru. *Journal of Nutrition*, 129: 1563 1568.
2. Caulfield, L. E., Zavaleta, N. and Figueroa, A. (1999b). Adding Zinc to prenatal iron and folate supplements improves maternal and neonatal Zinc status in a Peruvian population. American *Journal of Clinical Nutrition,* 69: 1257-1263.
3. Cavdar, A. O., Babacan, E., Arcasoy, A., Ertein, U. (1980). Effect of nutrition on serum Zinc concentration during pregnancy in Turkish women. *American Journal of Clinical Nutrition,* 33: 542–544.
4. Chandler, P., Kochupurakkal, B. S., Alam, S., Richardson, A. L., Soybel D. I., and Kelleher, S. L. (2016). Subtype-specific accumulation of intracellular Zinc pools is associated with the malignant phenotype in breast cancer. *Molecular Cancer*, 15(1): 2.
5. Chevallet, M., Jarvis, L., Harel, A., Luche, S., Degot, S., Chapuis, V., Boulay, G., Rabilloud, T. and Bouron, A. (2014). Functional consequences of the over-expression of TRPC6 channels in HEK cells: impact on the homeostasis of Zinc. *Metallomics*, 6 (7): 1269 -1276.
6. Christudoss, P., Selvakumar, R., Fleming J. J., and Gopalakrishnan, G. (2011). Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. *Indian Journal of Urology*, 27(1): 14-48.
7. Cousins, R. J., Liuzzi J. P., and Lichten, L. A. (2006). Mammalian Zinc transport, trafficking, and signals. *Journal of Biological Chemistry*, 281(34): 24085-24089.
8. Cui, Y., Vogt, S., Olson, N., Glass A. G., and Rohan, T. E. (2007). Levels of Zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer. *Cancer Epidemiology: Biomarkers Preview*, 16(8): 1682-1685.
9. Di Silvestro1 R. A., Koch, E. and Linda Rakes. (2015). Moderately High Dose Zinc Gluconate or Zinc Glycinate: Effects on Plasma Zinc and Erythrocyte Superoxide Dismutase Activities in

Young Adult Women. *Biology of Trace Elements Research,* DOI 10.1007/s12011-015 0334-3.

1. Ferguson, E. L., Gibson, R. S., Opare-Obisaw,

C., Ounpuu, S., Thompson, L. U. and Lehrfeld, J. (1993). The Zinc nutriture of preschool children living in two African countries. *Journal of Nutrition*, 123: 1487-1496.

1. Flora, S.J. S. and Tandon, S. K. (1990). Beneficial effects of Zinc supplementation during chelation treatment of lead intoxication in rats. *Toxicology,* 64: 129-139.
2. Fregoneze, J. B., Luz, C. P., Castro, L., P.

Oliveira, O., Lima, A. K. S., Souza, F., Maldonado, I., Macêdo, D. F., Ferreira, M.G., Bandeira, I. P. V., Rocha Jr., M. A., Carvalho, F. L. Q. and De-Castro-e-Silva, E. (1999). Zinc and water intake in rats: investigation of adrenergic and opiatergic central mechanisms. *Brazilian Journal of Medical and Biological Research*, 32: 1217-1222.

1. Fukunaka, A., and Kambe. T. (2010). Mechanism of Zinc transport by Zinc transporters, ZincT and ZIP. *Seikagaku*, 82(1): 30-34.
2. Gaither, L. A., and Eide, D. J. (2001). Eukaryotic Zinc transporters and their regulation. *Biometals*, 14(3-4): 251-270.
3. Gao, B., Li, K., Wei, Y. Y., Zhang, J., Gao, J. P., Li, Y. Y., Huang, L. G., Lin, P. and Wei, Y. Q. (2014). Zinc finger protein 637 protects cells against oxidative stress-induced premature senescence by mTERT-mediated telomerase activity and telomere maintenance. *Cell Death Diseases,* 5: 1334.
4. Ghasem, S., Jalali, M. A., Sarkaki, R. A., Karani, K., and Ahangarpoor, A. (2016). Effect of supplementation of Zinc on fertilization capacity of male rats exposed to noise stress. *International Journal of Pharmaceutical and Allied Sciences*, 5(2): 67-74.
5. Ghishan, F. K. (1984). Transport of electrolytes, water and glucose in Zinc deficiency. *Journal of Pediatrics and Gastroenteral Nutrition,* 3: 608612.
6. Golan, Y., Berman B. and Assaraf, Y. G. (2015). Heterodimerization, altered subcellular localization, and function of multiple Zinc transporters in viable cells using bimolecular fluorescence complementation. *Journal of Biological Chemistry*, 290(14): 9050-9063.
7. Goldenberg, R. L., Tamura, T., Neggers, Y., Copper, R. L., Johnson, K. E., Du Bard, M. B. and Hauth, J. C. (1995). The effect of Zinc supplementation on pregnancy outcome. *Journal of American Medical Association,* 274: 463-468.
8. Golovine, K., Uzzo, R. G., Makhov, P., Crispen, P. L., Kunkle, D. and Kolenko, V. M. (2008). Depletion of intracellular Zinc increases expression of tumourigenic cytokines VEGF, IL 6 and IL-8 in prostate cancer cells via NF-kappa B-dependent pathway. *Prostate*, 68(13): 14431449.
9. Grigorescu, R., Gruia, M. I., Nacea, V., Nitu, C. (2015). Parameters of oxidative stress variation depending on the concentration of inorganic Zinc compounds. *Journal of Medicine and Life.* 8(4): 449–451.
10. Haase, H. and Maret, W. (2003)*.* Intracellular Zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signalling. *Experimental Cellular Research,* 291: 289–298.
11. Haase, H. and Maret, W. (2005)*.* Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of Zinc and oxidants. *Biometals,* 18: 333–338.
12. Haase, H. and Rink, L. (2014)*.* Zinc signals and immune function*. Biofactors,* 40: 27–40.
13. Haase, H., Ober-Blobaum, J. L., Engelhardt, G., Hebel, S., Heit, A., Heine, H. and Rink, L. (2008)*.* Zinc signals are essential for lipopolysaccharide-induced signal transduction in monocytes. *Journal of Immunology,* 181: 6491–6502.
14. Han, C. T., Schoene, N. W. and Lei, K. Y.

(2009). Influence of Zinc deficiency on AktMdm2 p53 and Akt-p21 signalling axes in normal and malignant human prostate cells. *American Journal of Physiology: Cell*

*Physiology*, 297(5): 1188-1199.

1. Hansson, A. (1996)*.* Extracellular Zinc ions induces mitogen-activated protein kinase activity and protein tyrosine phosphorylation in bombesin-sensitive Swiss 3T3 fibroblasts. *Archives of Biochemistry and Biophysics,* 328: 233–238.
2. Ho, E., and Ames, B. N. (2002). Low intracellular Zinc induces oxidative DNA damage, disrupts p53, NFkappa B, and AP1 DNA binding, and affects DNA repair in a rat glioma cell line. *Proceedings of the National Academy of Sciences, U S A*, 99(26): 1677016775.
3. Hojyo, S., Fukada, T., Shimoda, S., Ohashi, W.,

Bin, B. H. Koseki, H. and Hirano, T. (2011)*.* The Zinc transporter SLC39A14/ZIP14 controls Gprotein coupled receptor-mediated signalling required for systemic growth*. PLoS One,* 6: 18059.

1. Hou, S., Vigeland, L. E., Zhang, G., Xu, R., Li, M., Heinemann, S. H., and Hoshi, T. (2010). Zinc2 + activates large conductance Ca2+activated K+channel via an intracellular domain. *Journal of Biological Chemistry*, 285 (9): 64346442.
2. Inoue, K., O'Bryant, Z. and Xiong, Z. G. (2015). Zinc-permeable ion channels: effects on intracellular Zinc dynamics and potential physiological/pathophysiological significance. *Current issues in Medicinal Chemistry*, 22(10): 1248-1257.
3. Jackson, M. J. (1989)*.* Physiology of Zinc: general aspects. In: *Zinc in Human Biology,* edited by Mills, C. F. New York: *Springer, p. 1– 14.*
4. Jemaia, H., Messaoudib, I., Chaouchc, A. and Kerkeni, A. (2007). Protective effect of Zinc supplementation on blood antioxidant defence system in rats exposed to cadmium. *Journal of Trace Elements in Medicine and Biology*, 21: 269–273.
5. Jiang, Q., Papasian, C. J., Wang, J. Q., Xiong Z. G., and Chu. X. P. (2010). Inhibitory regulation of acid-sensing ion channel 3 by Zinc. *Neuroscience*, 169(2): 574-583.
6. Kambe, T., Tsuji, T., Hashimoto, A., and Itsumura, N. (2015). The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism. *Physiological Review*, 95(3): 749784.
7. Khalaf, A. A., Ibrahim, M. A., Tohamy, A. F., Abd Allah, A. A. and Amr R. Z. (2017).

Protective Effect of Vita Zinc on Chlorsan

Induced Oxidative Stress, Genotoxicity and Histopathological Changes in Testicular Tissues of Male Rats. *International Journal of Pharmacology,* 13: 22-32.

1. Kikafunda, J. K., Walker, A. F., Allen, E. F. and Tumwine, J. K. (1998). Effect of Zinc supplementation on growth and body composition of Ugandan preschool children: a randomized, controlled intervention trial. *American Journal of Clinical Nutrition*, 68: 1261-1266.
2. King, J. C., Shames, D. M. and Woodhouse, L. R. (2000). Zinc homeostasis in humans. *Journal of Nutrition*, 130 (5): 1360-1366.
3. Kitamura, H., Morikawa, H., Kamon, H., Iguchi,

M., Hojyo, S., Fukada, T., Yamashita, S., Kaisho, T., Akira, S., Murakami, M. and Hirano, T. (2006). Toll-like receptor-mediated regulation of Zinc homeostasis influences dendritic cell function. *National journal of Immunology,* 7: 971–977.

1. Kochanczyk, T., Drozd, A. and Krezel, A*.*

(2015).Relationship between the architecture of Zinc coordination and Zinc binding affinity in proteins–insights into Zinc regulation. *Metallomics* 7: 244–257.

1. Krebs, N. F. (2013)*.* Update on Zinc deficiency and excess in clinical pediatric practice. *Annals of Nutrition and Metabolism,* 62 (1): 19–29.
2. Maret, W. (2013)*.* Zinc biochemistry: from a single Zinc enzyme to a key element of life. *Advances in Nutrition,* 4: 82–89.
3. Marger, L., Schubert C. R., and Bertrand, D. (2014). Zinc: an underappreciated modulatory factor of brain function. *Biochemistry and Pharmacology*, 91(4): 426-435.
4. Masayoshi, Y. and Satoshi, U. (2003). Preventive effect of Zinc acexamate administration in streptozotocin-diabetic rats: Restoration of bone loss. *International journal of molecular medicine,* 12: 755-761.
5. Menezo, Y., Pluntz, L., Chouteau, J., Gurgan, T. and Demirol, A. (2011). Zinc concentrations in serum and follicular fluid during ovarian stimulation and expression of Zinc2+ transporters in human oocytes and cumulus cells. *Reproductive Biomedicine Online*, 22: 647-652.
6. Merialdi, M, Caulfield, L. E., Zavaleta, N.,

Figueroa, A. and Di Pietro, J. A. (1998). Adding Zinc prenatal iron and folate tablets improves foetal neurobehavioral development. *American Journal of Obstetrics and Gynaecology*, 180: 483-490.

1. Meunier, N., Feillet-Coudray, C., Rambeau, M.,

Andriollo-Sanchez, M., Brandolini-Bunlon, M.,

Coulter, S. J., Cashman, K. D., Mazur A., and Coudray. C. (2005). Impact of micronutrient dietary intake and status on intestinal Zinc absorption in late middle-aged men: the ZENITH study. *European Journal of Clinical Nutrition*, 59 (2): 48-52.

1. Miyai, T., Hojyo, S., Ikawa, T., Kawamura, M.,

Irie, T., Ogura, H., Hijikata, A., Bin, B. H.,

Yasuda, T., Kitamura, H., Nakayama, M., Ohara,

O., Yoshida, H., Koseki, H., Mishima, K. and

Fukada, T. (2014)*.* Zinc transporter SLC39A10/ZIP10 facilitates antiapoptotic signalling during early B-cell development. *Proceedings of National Academy of Sciences, USA,* 111: 11780–11785.

1. Myers, S. A., Nield, A., Chew, G. S. and Myers,
	1. A. (2013). The Zinc transporter, Slc39a7 (Zip7) is implicated in glycaemic control in skeletal muscle cells. *PLoS One,* 8: 79316.
2. Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn,
	1. B., Donovan, A., Ward, D. M., Ganz, T. and Kaplan, J*.* (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science,* 306: 2090– 2093.
3. Nidia, N. G., Biaggio, V. S., Ciminari, M. E., María V. Pérez Chaca, M. V. and Álvarez, S. M. (2016). Zinc: What Is Its Role in Lung Cancer?.

In book: Nutritional Deficiency.

1. Nunes, R., Pasko, P., Tyszka-Czochara, M., Szewczyk, A., Szlosarczyk, M. and Carvalho, I. S. (2017). Antibacterial, antioxidant and antiproliferative properties and Zinc content of five south Portugal herbs. *Pharmacology and*

*Biology,* 55 (1): 114-123.

1. Ozkaya, M. O., Naziroglu, M., Barak, C., Berkkanoglu, M. (2011). Effects of multivitamin/mineral supplementation on trace element levels in serum and follicular fluid of women undergoing in vitro fertilization (IVF). *Biological Trace Element Research,* 139: 1-9.
2. Pan, Z., Choi, S., Ouadid-Ahidouch, H., Yang, J, Beattie, J. H. and Korichneva, I. (2017). Zinc transporters and dysregulated channels in cancers. *Frontiers in Bioscience (Landmark Ed).* 22: 623-643.
3. Prasad, A. S. (2013). Discovery of human Zinc deficiency: its impact on human health and disease. *Advances in Nutrition*, 4(2): 176-90.
4. Prasad, A. S. (2014a). Impact of the discovery of human Zinc deficiency on health. *Journal of Trace Element in Medicine and Biology*, 28(4): 357-363.
5. Prasad, A. S. (2014). Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health. *Frontiers in Nutrition*, 1: 14.
6. Prasad, A. S., Bao, B., Beck, F. W, Sarkar, F. H. (2001). Zinc activates NF-κB in HUT-78 cells.

*Journal of Laboratory Clinical Medicine,* 138: 250–255.

1. Prasad, A. S., Bao, B., Beck, F. W. J., Kucuk,

O., Sarkar, F. H. (2004). Antioxidant effect of Zinc in humans. *Free Radicals in Biology and Medicine,* 37: 1182–1190.

1. Punthambaker, S., Blum, J. A. and Hume, R. I.

(2012). High potency Zinc modulation of human P2X2 receptors and low potency Zinc modulation of rat P2X2 receptors share a common molecular mechanism. *Journal of Biological Chemistry*, 287(26): 22099-22111.

1. Rukgauer, M., Klein J., and Kruse-Jarres. J. D. (1997). Reference values for the trace elements copper, manganese, selenium, and Zinc in the serum/plasma of children, adolescents, and adults. *Journal of Trace Elements in Medical Biology*, 11(2): 92-8.
2. Sandstead, H. H., Penland, J. G., Alcock, N. W.,

Dayal, H. H., Chen, X. C., Li, J. S., Zhoa, F. and Yang, J. J. (1998). Effects of repletion with Zinc and other micronutrients on neuropsychologic preformance and growth of Chinese children. *American Journal of Clinical Nutrition,* 68: 470475.

1. Sazawal, S., Bentley, M., Black, R. E., Dhingra,

P., George, S. and Bhan, M. K. (1996). Effect of

Zinc supplementation on observed activity in low socioeconomic Indian preschool children. *PEDS 98*: 1132-1137.

1. Sharir, H., Zinger, A., Nevo, A., Sekler, I. and Hershfinkel, M*.* (2010).Zinc released from injured cells is acting via the Zinc2+-sensing receptor, ZincR, to trigger signalling leading to epithelial repair. *Journal of Biological Chemistry,* 285: 26097–26106.
2. Solomons, N. W., Ruz, M. and Gibson, R. S. (1999) Single-nutrient interventions with Zinc. *American Journal of Clinical Nutrition*, 70: 111113.
3. Takeda, A., Nakamura, M., Fujii, H. and Tamano, H*.* (2013).Synaptic Zinc2+ homeostasis and its significance. *Metallomics,* 5: 417–423*.*
4. Tamaki, M., Fujitani, Y., Hara, A., Uchida, T.,

Tamura, Y., Takeno, K., Kawaguchi, M.,

Watanabe, T., Ogihara, T., Fukunaka, A., Shimizu, T., Mita, T., Kanazawa, A., Imaizumi, M. O., Abe, T., Kiyonari, H., Hojyo, S., Fukada,

T., Kawauchi, T., Nagamatsu, S., Hirano, T., Kawamori, R. and Watada, H. (2013)*.* The diabetes susceptible gene SLC30A8/ZincT8 regulates hepatic insulin clearance*. Journal of Clinical Investigation,* 123: 4513–4524.

1. Taylor, K. M., Hiscox, S., Nicholson, R. I., Hogstrand, C. and Kille, P. (2012). Protein kinase CK2 triggers cytosolic Zinc signalling pathways by phosphorylation of Zinc channel ZIP7*. Science Signal,* 5:1.
2. Traboulsie, A., Chemin, J., Chevalier, M., Quignard, J. F., Nargeot J. and Lory. P. (2007). Subunit-specific modulation of T-type calcium channels by Zinc. *Journal of Physiology*, 578 (1): 159-171.
3. Uchida, K., and Tominaga. M. (2013).

Extracellular Zinc ion regulates transient receptor potential melastatin 5 (TRPM5) channel activation through its interaction with a pore loop domain. *Journal of Biological Chemistry*, 288(36): 25950-25955.

1. Vallee, B. L. and Falchuk, K. H. (1993)*.* The biochemical basis of Zinc physiology.

*Physiological Reviews,* 73: 79–118.

1. Vimala, K., Shanthi, K., Sundarraj, S. and Kannan, S. (2017). Synergistic effect of chemo photothermal for breast cancer therapy using folic acid (FA) modified Zinc oxide nanosheet. *Journal of Colloid Interface Science.* 488: 92108.
2. Vegetarian Nutrition Dietetic Practice Group (2013). *Zinc:* *Fact Sheet for Health Professionals.* National Institutes of Health. Office of Dietary Supplements, 2013.
3. Walravens, P. A. and Hambidge, K. M. (1976) Growth of infants fed a Zinc supplemented formula. *American Journal of Clinical Nutrition*, 29: 1114-1121.
4. Wilson, M., Hogstrand, C. and Maret, W.

(2012)*.* Picomolar concentrations of free Zinc (II) ions regulate receptor protein-tyrosine phosphatase beta activity. *Journal of Biology and Chemistry,* 287: 9322–9326.

1. Wood, R. (2000). Assessing marginal Zinc deficiency: where are we now and where are we going in the future? *Journal of Nutrition,* 130: 1350-1354.
2. Wu, X., Tang, J., and Xie, M. (2015). Serum and hair Zinc levels in breast cancer: A Meta analysis. *Science Report*, 5: 12249.
3. Zinc for Child Health (1997). Acrodermatitis in breast-fed premature infants: evidence for a defect of mammary Zinc secretion. *Child Health Resource Project Special Report.* The John Hopkins University Baltimore, MD.

5/21/2017